Skip to content

Esperion Therapeutics ESPR Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin18.1%+31.8pp15%-2.7pp-8.2%-13.8pp-11.6%-13.4pp-13.7%+1.4pp
Efficiency
Asset turnover1.1×+0.3×-0.2×0.9×-0.2×0.8×-0.2×0.7×0.0×
Liquidity
Current ratio1.5×+0.4×1.5×+0.2×-0.9×1.1×-0.8×1.2×-1.0×
Leverage
Net debt / EBITDA-0×-0.2×-0.2×
Per Share
Book value per share-$1.23+43.6%-$1.45+30.0%-$2.25-18.4%-$2.19-20.4%-$2.17-40.0%
Valuation
Market capitalization$811.73M+283%$877.16M+102%$534.3M+65.0%$212.07M-49.6%$284.9M-42.6%
Price / sales1.9×+1.1×2.2×+0.9×1.8×+0.7×0.8×-0.7×1.1×-1.1×
EV / EBITDA10.7×14.3×+6.9×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Esperion Therapeutics's ratios come from?
Every ratio is computed from Esperion Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.